Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
A M MenziesS N LoR P M SawM GonzalezS Ch'ngO E NiewegK F ShannonP M FergusonJ LeeL EmmettR KapoorR V RawsonJ R StretchJ F ThompsonA J SpillaneH RizosR A ScolyerG V LongPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
Neoadjuvant dabrafenib plus trametinib has high pathological response rates in clinical stage III melanoma, but low rates of RFS, similar to those achieved with adjuvant targeted therapy alone. Patients with a pCR to dabrafenib plus trametinib still had a high risk of recurrence, unlike that seen with immunotherapy where recurrences are rare.